中国癌症症状管理实践指南—皮肤反应

2019-11-30 中国抗癌协会肿瘤护理专业委员会 护士进修杂志.2019.34(22):2017-2024.

本指南的构建严格遵循了美国医学研究所关于临床实践指南的最新定义,并以WHO标准指南制订方法学为依据,包括成立指南工作组、指南注册及计划书撰写、临床问题遴选和确定、证据检索及评价、推荐意见形成等流程。证据分级及推荐意见制订采用GRADE方法学,通过3轮面对面专家共识会,最终形成皮肤反应管理实践指南,共15条推荐意见。该指南涵盖了化疗和靶向治疗所致皮肤反应的常规皮肤护理、局部冷疗、防晒剂、芦荟胶和药物

中文标题:

中国癌症症状管理实践指南—皮肤反应

发布日期:

2019-11-30

简要介绍:

本指南的构建严格遵循了美国医学研究所关于临床实践指南的最新定义,并以WHO标准指南制订方法学为依据,包括成立指南工作组、指南注册及计划书撰写、临床问题遴选和确定、证据检索及评价、推荐意见形成等流程。证据分级及推荐意见制订采用GRADE方法学,通过3轮面对面专家共识会,最终形成皮肤反应管理实践指南,共15条推荐意见。该指南涵盖了化疗和靶向治疗所致皮肤反应的常规皮肤护理、局部冷疗、防晒剂、芦荟胶和药物治疗等方面,旨在为我国医务工作者和患者提供最佳决策工具。

 

拓展指南:皮肤相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国癌症症状管理实践指南—皮肤反应)] GetToolGuiderByIdResponse(projectId=1, id=c0e5c1c0018a1182, title=中国癌症症状管理实践指南—皮肤反应, enTitle=, guiderFrom=护士进修杂志.2019.34(22):2017-2024., authorId=null, author=, summary=本指南的构建严格遵循了美国医学研究所关于临床实践指南的最新定义,并以WHO标准指南制订方法学为依据,包括成立指南工作组、指南注册及计划书撰写、临床问题遴选和确定、证据检索及评价、推荐意见形成等流程。证据分级及推荐意见制订采用GRADE方法学,通过3轮面对面专家共识会,最终形成皮肤反应管理实践指南,共15条推荐意见。该指南涵盖了化疗和靶向治疗所致皮肤反应的常规皮肤护理、局部冷疗、防晒剂、芦荟胶和药物, cover=, journalId=null, articlesId=null, associationId=1859, associationName=中国抗癌协会肿瘤护理专业委员会, associationIntro= , copyright=0, guiderPublishedTime=Sat Nov 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>本指南的构建严格遵循了美国医学研究所关于临床实践指南的最新定义,并以WHO标准指南制订方法学为依据,包括成立指南工作组、指南注册及计划书撰写、临床问题遴选和确定、证据检索及评价、推荐意见形成等流程。证据分级及推荐意见制订采用GRADE方法学,通过3轮面对面专家共识会,最终形成皮肤反应管理实践指南,共15条推荐意见。该指南涵盖了化疗和靶向治疗所致皮肤反应的常规皮肤护理、局部冷疗、防晒剂、芦荟胶和药物治疗等方面,旨在为我国医务工作者和患者提供最佳决策工具。</P> <P> </P>拓展指南:<STRONG>与<FONT color=red>皮肤</FONT>相关指南:</STRONG><BR> <UL> <LI><A title="2019 JDA指南:皮肤黑色素瘤(概述)" target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=e77a91c0018362d1">2019 JDA指南:皮肤黑色素瘤(概述)</A> <LI><A title=NCCN临床实践指南:皮肤黑色素瘤(2019.V3) target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=1ddc61c00183262e">NCCN临床实践指南:皮肤黑色素瘤(2019.V3)</A> <LI><A title=免疫检查点抑制剂相关皮肤不良反应诊治建议 target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=dba161c00182516d">免疫检查点抑制剂相关皮肤不良反应诊治建议</A> <LI><A title=中国远程皮肤病学质量控制专家共识 target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=c6f491c0018233e7">中国远程皮肤病学质量控制专家共识</A> <LI><A title=单纯性和复杂性皮肤及软组织感染抗菌药物临床试验指导原则 target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=861781c00181e229">单纯性和复杂性皮肤及软组织感染抗菌药物临床试验指导原则</A> 更多信息请点击:<A target=_blank href="https://www.medsci.cn/guideline/list.do?q=%E7%9A%AE%E8%82%A4">有关皮肤更多指南</A></LI></UL>, tagList=[TagDto(tagId=34298, tagName=皮肤反应), TagDto(tagId=98144, tagName=癌症症状管理)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=79, categoryName=护理, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4572, appHits=213, showAppHits=0, pcHits=2523, showPcHits=2893, likes=68, shares=4, comments=6, approvalStatus=1, publishedTime=Tue Dec 24 20:35:20 CST 2019, publishedTimeString=2019-11-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Dec 24 20:35:20 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 22:12:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国癌症症状管理实践指南—皮肤反应)])
中国癌症症状管理实践指南—皮肤反应
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1076780, encodeId=c34310e6780ba, content=对临床还是有一定作用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3935460121, createdName=ms3000000818214730, createdTime=Sat Dec 04 11:04:17 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075025, encodeId=54ed10e5025e3, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86fa6152702, createdName=ms1000000368979776, createdTime=Mon Nov 29 11:14:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014717, encodeId=a36c1014e178a, content=写的很好,受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:26:48 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804675, encodeId=631a8046e51b, content=真心不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd921304684, createdName=471239581, createdTime=Sun Jul 26 23:45:45 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377391, encodeId=0bb93e739175, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Dec 25 05:29:38 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
    2021-12-04 ms3000000818214730

    对临床还是有一定作用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1076780, encodeId=c34310e6780ba, content=对临床还是有一定作用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3935460121, createdName=ms3000000818214730, createdTime=Sat Dec 04 11:04:17 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075025, encodeId=54ed10e5025e3, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86fa6152702, createdName=ms1000000368979776, createdTime=Mon Nov 29 11:14:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014717, encodeId=a36c1014e178a, content=写的很好,受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:26:48 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804675, encodeId=631a8046e51b, content=真心不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd921304684, createdName=471239581, createdTime=Sun Jul 26 23:45:45 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377391, encodeId=0bb93e739175, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Dec 25 05:29:38 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
    2021-11-29 ms1000000368979776

    非常有用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1076780, encodeId=c34310e6780ba, content=对临床还是有一定作用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3935460121, createdName=ms3000000818214730, createdTime=Sat Dec 04 11:04:17 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075025, encodeId=54ed10e5025e3, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86fa6152702, createdName=ms1000000368979776, createdTime=Mon Nov 29 11:14:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014717, encodeId=a36c1014e178a, content=写的很好,受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:26:48 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804675, encodeId=631a8046e51b, content=真心不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd921304684, createdName=471239581, createdTime=Sun Jul 26 23:45:45 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377391, encodeId=0bb93e739175, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Dec 25 05:29:38 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
    2021-09-05 pyunzhen

    写的很好,受教了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1076780, encodeId=c34310e6780ba, content=对临床还是有一定作用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3935460121, createdName=ms3000000818214730, createdTime=Sat Dec 04 11:04:17 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075025, encodeId=54ed10e5025e3, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86fa6152702, createdName=ms1000000368979776, createdTime=Mon Nov 29 11:14:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014717, encodeId=a36c1014e178a, content=写的很好,受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:26:48 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804675, encodeId=631a8046e51b, content=真心不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd921304684, createdName=471239581, createdTime=Sun Jul 26 23:45:45 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377391, encodeId=0bb93e739175, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Dec 25 05:29:38 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
    2020-07-26 471239581

    真心不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1076780, encodeId=c34310e6780ba, content=对临床还是有一定作用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3935460121, createdName=ms3000000818214730, createdTime=Sat Dec 04 11:04:17 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075025, encodeId=54ed10e5025e3, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86fa6152702, createdName=ms1000000368979776, createdTime=Mon Nov 29 11:14:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014717, encodeId=a36c1014e178a, content=写的很好,受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:26:48 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804675, encodeId=631a8046e51b, content=真心不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd921304684, createdName=471239581, createdTime=Sun Jul 26 23:45:45 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377391, encodeId=0bb93e739175, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Wed Dec 25 05:29:38 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
    2019-12-25 thm112988

    0